The role of Toll-like receptors (TLRs) in the CNS is only starting to be uncovered. As in peripheral organs, multiple TLRs are dynamically expressed. They are involved in mounting a host-defense ...response against microbial invasion of the CNS. The many different TLRs expressed on microglia are likely the most important first line of defense in this respect. Intriguingly, microglial TLR tend to trigger a very standard cytokine and chemokine response, irrespective of the type of TLR agonist they meet. The main purpose of this standardized response by microglia may be to recruit the assistance by other cells rather than to immediately mount a destructive response toward invaders. As is generally the case for microglial responses, TLR-mediated responses can also work out in either beneficial or detrimental ways, depending on the strength and timing of the activating signal. Yet, the role of TLRs in the CNS extends well beyond controlling host-defense responses alone. Other cells in the CNS, including astrocytes, neurons, and oligodendrocytes, can also express multiple functional TLRs upon activation. These play important roles in tissue development, cellular migration, and differentiation; in limiting inflammation; and in mounting repair processes following trauma. The TLR-mediated reactions of these other neural cells to TLR agonists is highly cell specific and does not necessarily resemble that of microglia at all. It appears likely that endogenous agonists for TLRs are particularly relevant to activate these endogenous TLR functions on neural cells, also during development when microbial invaders have not yet entered the stage. In this chapter, current data are reviewed to highlight the emerging variety of functional roles of TLRs in the CNS.
The family of Toll-like receptors (TLRs) plays a key role in controlling innate immune responses to a wide variety of pathogen-associated molecules. In this study we investigated expression of TLRs ...in vitro by purified human microglia, astrocytes, and oligodendrocytes, and in vivo by immunohistochemical examination of brain and spinal cord sections. Cultured primary microglia were found to express mRNA encoding a wide range of different TLR family members while astrocytes and oligodendrocytes primarily express TLR2 and TLR3. Comparisons between microglia derived from a series of control subjects and neurodegenerative cases indicate distinct differences in levels of mRNA encoding the different TLRs in different microglia samples. Interestingly, expression of TLR proteins in cultured microglia as revealed by immunocytochemistry was restricted to intracellular vesicles, whereas in astrocytes they were exclusively localized on the cell surface. Finally, in vivo expression of TLR3 and TLR4 was examined by immunohistochemical analysis of brain and spinal cord sections from both control and multiple sclerosis brains, revealing enhanced expression of either TLR in inflamed CNS tissues. Together, our data reveal broad and regulated expression of TLRs both in vitro and in vivo by human glia cells.
As a molecular chaperone and activator of Toll-like receptor 2-mediated protective responses by microglia and macrophages, the small heat shock protein alpha B-crystallin (HspB5) exerts therapeutic ...effects in different animal models for neuroinflammation, including the model for multiple sclerosis (MS). Yet, HspB5 can also stimulate human antigen-specific memory T cells to release IFN-γ, a cytokine with well-documented detrimental effects during MS. In this study, we explored in a Phase IIa randomized clinical trial the therapeutic application of HspB5 in relapsing-remitting MS (RR-MS), using intravenous doses sufficient to support its protective effects, but too low to trigger pathogenic memory T-cell responses. These sub-immunogenic doses were selected based on in vitro analysis of the dose-response profile of human T cells and macrophages to HspB5, and on the immunological effects of HspB5 in healthy humans as established in a preparatory Phase I study. In a 48-week randomized, placebo-controlled, double-blind Phase IIa trial, three bimonthly intravenous injections of 7.5, 12.5 or 17.5 mg HspB5 were found to be safe and well tolerated in RR-MS patients. While predefined clinical endpoints did not differ significantly between the relatively small groups of MS patients treated with either HspB5 or placebo, repeated administration especially of the lower doses of HspB5 led to a progressive decline in MS lesion activity as monitored by magnetic resonance imaging (MRI), which was not seen in the placebo group. Exploratory linear regression analysis revealed this decline to be significant in the combined group receiving either of the two lower doses, and to result in a 76% reduction in both number and total volumes of active MRI lesions at 9 months into the study. These data provide the first indication for clinical benefit resulting from intervention in RR-MS with HspB5.
ClinicalTrials.gov Phase I: NCT02442557; Phase IIa: NCT02442570.
Celotno besedilo
Dostopno za:
DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
Progressive neuronal death during tauopathies is associated with aggregation of modified, truncated or mutant forms of tau protein. Such aggregates are neurotoxic, promote spreading of tau ...aggregation, and trigger release of pro-inflammatory factors by glial cells. Counteracting such pathogenic effects of tau by simultaneously inhibiting protein aggregation as well as pro-inflammatory glial cell responses would be of significant therapeutic interest. Here, we examined the use of the small heat-shock protein HspB5 for this purpose. As a molecular chaperone, HspB5 counteracts aggregation of a wide range of abnormal proteins. As a TLR2 agonist, it selectively activates protective responses by CD14-expressing myeloid cells including microglia. We show that intracerebral infusion of HspB5 in transgenic mice with selective neuronal expression of mutant human P301S tau has significant neuroprotective effects in the superficial, frontal cortical layers. Underlying these effects at least in part, HspB5 induces several potent neuroprotective mediators in both astrocytes and microglia including neurotrophic factors and increased potential for removal of glutamate. Together, these findings highlight the potentially broad therapeutic potential of HspB5 in neurodegenerative proteinopathies.
The glial stress protein alpha B‐crystallin (HSPB5) is an endogenous agonist for Toll‐like receptor 2 in CD14+ cells. Following systemic administration, HSPB5 acts as a potent inhibitor of ...neuroinflammation in animal models and reduces lesion development in multiple sclerosis patients. Here, we show that systemically administered HSPB5 rapidly crosses the blood–brain barrier, implicating microglia as additional targets for HSPB5 along with peripheral monocytes and macrophages. To compare key players in the HSPB5‐induced protective response of human macrophages and microglia, we applied weighted gene co‐expression network analysis on transcript expression data obtained 1 and 4 h after activation. This approach identified networks of genes that are co‐expressed in all datasets, thus reducing the complexity of the nonsynchronous waves of transcripts that appear after activation by HSPB5. In both cell types, HSPB5 activates a network of highly connected genes that appear to be functionally equivalent and consistent with the therapeutic effects of HSPB5 in vivo, since both networks include factors that suppress apoptosis, the production of proinflammatory factors, and the development of adaptive immunity. Yet, hub genes at the core of the network in either cell type were strikingly different. They prominently feature the well‐known tolerance‐promoting programmed‐death ligand 1 as a key player in the macrophage response to HSPB5, and the immune‐regulatory enzyme cyclooxygenase‐2 (COX‐2) in that of microglia. This latter finding indicates that despite its reputation as a potential target for nonsteroidal anti‐inflammatory drugs, microglial COX‐2 plays a central role in the therapeutic effects of HSPB5 during neuroinflammation. GLIA 2017;65:460–473
Main Points
Systemic alpha B‐crystallin (HSPB5) triggers activation of both peripheral macrophages and brain microglia.
The protective macrophage and microglial response to HSPB5 are functionally similar, but controlled by different co‐expressed hub genes.
TLR3 recognizes dsRNAs and is considered of key importance to antiviral host-defense responses. TLR3 also triggers neuroprotective responses in astrocytes and controls the growth of axons and ...neuronal progenitor cells, suggesting additional roles for TLR3-mediated signaling in the CNS. This prompted us to search for alternative, CNS-borne protein agonists for TLR3. A genome-scale functional screening of a transcript library from brain tumors revealed that the microtubule regulator stathmin is an activator of TLR3-dependent signaling in astrocytes, inducing the same set of neuroprotective factors as the known TLR3 agonist polyinosinic:polycytidylic acid. This activity of stathmin crucially depends on a long, negatively charged alpha helix in the protein. Colocalization of stathmin with TLR3 on astrocytes, microglia, and neurons in multiple sclerosis-affected human brain indicates that as an endogenous TLR3 agonist, stathmin may fulfill previously unsuspected regulatory roles during inflammation and repair in the adult CNS.
Abstract
Background
Microglia are resident immune effector cells in the CNS and play an essential role in neuroinflammation, ischemic and neurodegenerative disease. Therefore, microglia cells are ...considered a potential therapeutic target for neurodegenerative diseases. To fully understand the role of microglia, the preferred strategy would be to study primary human microglia isolated from post‐mortem human brain tissue. Microglia can be isolated from both control and diseased human brain tissue with confirmed neuropathology. However, the obvious limitation on brain collection and yield of isolated cells restricts the ability to perform screening studies. Induced pluripotent stem cells (iPSCs)‐derived microglia, may provide a suitable alternative for screening studies and large‐scale compound validation. Yet, to effectively use iPSC‐derived microglia, one must characterize the extent to which these cells faithfully represent biological processes in primary brain tissue.
Method
Here, we compared the gene expression and cytokine release from primary human microglia cells obtained from tissue provided by the Netherlands Brain Bank and iPSC‐derived microglia.
Result
Exposure of primary and iPSC‐derived microglia to LPS resulted in increased TNF‐α secretion in a concentration and time dependent manner. LPS‐mediated TNF‐α secretion was strongly inhibited by dexamethasone. Priming of primary and iPSC‐derived microglia with LPS and treatment with nigericin, a potent inflammasome activator, resulted in robust secretion of IL‐1β and IL‐18. Furthermore, nigericin induced IL‐1β and IL‐18 release was blocked by the inflammasome inhibitor MCC950 in both cell types. In addition, similarly to in‐house differentiated microglia, commercially available iPSC‐derived microglia (Bit.bio) showed a strong expression of specific markers as well as cytokine response upon LPS treatment.
Conclusion
Taken together, we successfully demonstrated that primary and iPSC‐derived microglia respond similarly to LPS and nigericin treatment. For these reasons, these cell types could serve as a reliable tool for evaluating the potency and efficacy of prospective drugs for multiple neurological diseases associated with microglia activation, such as Alzheimer’s and Parkinson’s Disease.